Literature DB >> 24763266

Pharmacokinetic properties of arsenic species after oral administration of Sargassum pallidum extract in rats using an HPLC-HG-AFS method.

Yan Cao1, Jinao Duan2, Jianming Guo1, Weixia Li1, Weiwei Tao1.   

Abstract

Sargassum pallidum is one of the Traditional Chinese Medicine widely used for phlegm elimination and detumescence. Arsenic is present in high concentration in seaweed belonging to the genus Sargassum. Therefore, the consumption of S. pallidum is a route of exposure to arsenic. Since the toxicity of arsenic is highly dependent on its chemical speciation, the determination of total arsenic is not adequate to assess the risks. Here, a high performance liquid chromatography-hydride generation-atomic fluorescence spectrometry (HPLC-HG-AFS) was developed for determination of the common arsenic species including arsenite [As(III)], dimethylarsinate (DMA), methylarsonate (MMA) and arsenate [As(V)] simultaneously. This method was applied to study the pharmacokinetic profile of these arsenic species in rats after oral administration of S. pallidum extract at different doses. The described assay was validated for limit of quantification, linearity, intra-day and inter-day precisions, accuracy, extraction recovery and stability according to the FDA validation guidelines. As(III) or MMA was not detected in any samples collected at all time points using the present HPLC-HG-AFS method. As(V) and DMA in the S. pallidum could be readily absorbed and eliminated in rats. A trend of dose-dependence was shown for DMA and As(V) in the drug concentration-time profiles. This study would be helpful for the apprehension of the action mechanism and clinical application of medicinal seaweeds.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arsenic species; HPLC-HG-AFS; Pharmacokinetics; Rat plasma; Sargassum pallidum

Mesh:

Substances:

Year:  2014        PMID: 24763266     DOI: 10.1016/j.jpba.2014.03.045

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Accumulation of Arsenic Speciation and In Vivo Toxicity Following Oral Administration of a Chinese Patent Medicine Xiao-Er-Zhi-Bao-Wan in Rats.

Authors:  Jiaoyang Luo; Xu Han; Xiaowen Dou; Lei Zhang; Shihai Yang; Meihua Yang
Journal:  Front Pharmacol       Date:  2017-07-25       Impact factor: 5.810

2.  Development of a UPLC-TQ/MS Approach for the Determination of Eleven Bioactive Components in Haizao Yuhu Decoction Plus-Minus Haizao and Gancao Drug Combination after Oral Administration in a Rat Model of Hypothyroidism.

Authors:  Yingchang Ma; Yang Zhang; Yuanjuan Zhai; Zhenhua Zhu; Ying Pan; Dawei Qian; Shulan Su; Xinsheng Fan; Jinao Duan
Journal:  Molecules       Date:  2016-12-22       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.